Uncategorized

Attaining China’s Speed Domestically and Why It Matters for RNA Therapeutics

February 10, 2026 / February 13, 2026 by Dawn Lam

Over the past decade, China has implemented sweeping reforms that dramatically shortened drug development cycles and streamlined clinical trial approvals. A major driver of this acceleration is China’s long-term, innovation-focused policy agenda. Under the 14th and 15th Five‑Year Plans, the government emphasized biological manufacturing, precision medicine, and innovation‑led growth, signaling a shift from infrastructure expansion […]

Read more »